𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of depression in Parkinson's disease with moclobemide: A pilot open-label study

✍ Scribed by S. Giménez-Roldán; J.L. Dobato; D. Mateo

Book ID
117755400
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
843 KB
Volume
3
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Caffeine in Parkinson's disease: A pilot
Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
✍ Robert D. Altman; Anthony E. Lang; Ronald B. Postuma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB 👁 1 views

## Abstract ## Introduction: Epidemiologic studies consistently find an inverse association between caffeine use and PD. Numerous explanations exist, but are difficult to evaluate as caffeine's symptomatic effect and tolerability in PD are unknown. ## Patients and Methods: We designed an open‐la

Atomoxetine for the treatment of executi
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

CQP 201-403 in Parkinson's disease: An o
CQP 201-403 in Parkinson's disease: An open-label pilot study
✍ Dr. Ronald F. Pfeiffer; Leonel H. Herrera; Carolyn S. Glaeske; Ruth E. Hofman 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 1 views

The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over a n average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in suffici

Symptomatic relief from treatment-induce
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: An open-label pilot study with remoxipride
✍ Dr. Tilak Mendis; Erich Mohr; Amanda George; Ilene N. Rusk; Peggy Gray; J. David 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 1 views

## Abstract Current treatment strategies for levodopa‐induced psychosis in Parkinson's disease have had limited success. Remoxipride, a selective D~2~ receptor antagonist, was administered in an open label pilot study to seven parkinsonian patients exhibiting thought disorder. Symptoms improved sig

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; John L. Maldonado; William O. Tatum; Ro 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and wer